CN102526203B - 一种具有抗糖尿病肾病作用的香椿子提取物制备方法 - Google Patents
一种具有抗糖尿病肾病作用的香椿子提取物制备方法 Download PDFInfo
- Publication number
- CN102526203B CN102526203B CN201210024221.3A CN201210024221A CN102526203B CN 102526203 B CN102526203 B CN 102526203B CN 201210024221 A CN201210024221 A CN 201210024221A CN 102526203 B CN102526203 B CN 102526203B
- Authority
- CN
- China
- Prior art keywords
- extract
- tonnae sinensis
- diabetic nephropathy
- group
- chinese toona
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000284 extract Substances 0.000 title claims abstract description 23
- 230000000694 effects Effects 0.000 title claims abstract description 18
- 208000007342 Diabetic Nephropathies Diseases 0.000 title abstract description 8
- 208000033679 diabetic kidney disease Diseases 0.000 title abstract description 8
- 241000949476 Toona Species 0.000 title abstract 6
- 235000013399 edible fruits Nutrition 0.000 title abstract 6
- 238000002360 preparation method Methods 0.000 title description 5
- 238000000034 method Methods 0.000 claims abstract description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- 239000003208 petroleum Substances 0.000 claims description 12
- 239000002024 ethyl acetate extract Substances 0.000 claims description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- 125000001033 ether group Chemical group 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 7
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 208000017169 kidney disease Diseases 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 241000196324 Embryophyta Species 0.000 abstract description 4
- 239000002904 solvent Substances 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000011156 evaluation Methods 0.000 abstract 1
- 238000011617 nephropathy animal model Methods 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 24
- 210000002700 urine Anatomy 0.000 description 12
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 230000037396 body weight Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000003907 kidney function Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 3
- 230000009897 systematic effect Effects 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 241000050051 Chelone glabra Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010038468 Renal hypertrophy Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 201000008627 kidney hypertrophy Diseases 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组 别 | 动物数(只) | 体重(g) | 肾重体重比(×103) |
空白对照组 | 10 | 326.7±24.5 | 3.61±0.92 |
模型对照组 | 10 | 172.4±16.8▲▲ | 6.25±0.71▲▲ |
石油醚部位组 | 12 | 185.5±17.6 | 6.33±0.64 |
乙酸乙酯部位组 | 12 | 191.3±18.2★ | 5.52±0.44★★ |
正丁醇部位组 | 12 | 261.8 ±19.3★★ | 4.70±0.52★★ |
水部位组 | 12 | 186.2±16.7 | 5.83±0.60 |
组 别 | 动物数(只) | 24 h尿量(ml) | 24 h UMA(mg) |
空白对照组 | 10 | 9.63±3.20 | 14.76±1.85 |
模型对照组 | 10 | 131.5±24.6▲▲ | 50.29±4.73▲▲ |
石油醚部位组 | 12 | 130.4±18.7 | 50.11±30.69 |
乙酸乙酯部位组 | 12 | 109.8±12.6★ | 46.32±3.15★ |
正丁醇部位组 | 12 | 105.2±10.1★★ | 43.86±4.07★★ |
水部位组 | 12 | 129.6±13.3 | 49.54±5.05 |
组 别 | 动物数(只) | BUN(mmol/L) | Cr(μmol/L) |
空白对照组 | 10 | 6.39±0.58 | 64.35±9.47 |
模型对照组 | 10 | 18.47±3.56▲▲ | 98.72±12.34▲▲ |
石油醚部位组 | 12 | 15.82±2.84 | 90.26±11.05 |
乙酸乙酯部位组 | 12 | 14.51±3.73★ | 87.65±9.78★ |
正丁醇部位组 | 12 | 10.06±1.85★★ | 78.54±6.83★★ |
水部位组 | 12 | 16.24±2.25 | 89.71±10.17 |
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210024221.3A CN102526203B (zh) | 2012-02-05 | 2012-02-05 | 一种具有抗糖尿病肾病作用的香椿子提取物制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210024221.3A CN102526203B (zh) | 2012-02-05 | 2012-02-05 | 一种具有抗糖尿病肾病作用的香椿子提取物制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102526203A CN102526203A (zh) | 2012-07-04 |
CN102526203B true CN102526203B (zh) | 2014-03-12 |
Family
ID=46335024
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210024221.3A Expired - Fee Related CN102526203B (zh) | 2012-02-05 | 2012-02-05 | 一种具有抗糖尿病肾病作用的香椿子提取物制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102526203B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI538682B (zh) * | 2013-01-17 | 2016-06-21 | Nat Univ Chung Hsing | The use of the extract toon |
-
2012
- 2012-02-05 CN CN201210024221.3A patent/CN102526203B/zh not_active Expired - Fee Related
Non-Patent Citations (9)
Title |
---|
.< * |
.2010,第*卷(第*期),中国重要会议论文全文数据库出版页. * |
广东省药学会2009学术年会论文集> * |
张俊芳 * |
杨敏 * |
温劲 * |
等.< * |
等.< 香椿乙醇提取物对糖尿病模型小鼠降血糖作用的初步研究 >.<广东省药学会2009学术年会论文集>.2010,第*卷(第*期),中国重要会议论文全文数据库出版页. |
香椿乙醇提取物对糖尿病模型小鼠降血糖作用的初步研究 > * |
Also Published As
Publication number | Publication date |
---|---|
CN102526203A (zh) | 2012-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10624938B2 (en) | Total flavone extract of flower of abelmoschus manihot L. medic and preparation method thereof | |
CN102038720B (zh) | 一种桦褐孔菌降血糖有效部位及其制备方法与应用 | |
CN102178741B (zh) | 具有降血糖作用的番石榴叶提取物及其制备方法与应用 | |
CN107441078A (zh) | 一种治疗糖尿病的药物组合物及其制备方法和用途 | |
CN104173451B (zh) | 一种天然药物组合物在降血糖药品及保健食品中的应用 | |
CN107349244B (zh) | 丙二酰基人参皂苷的提取方法 | |
CN103989724B (zh) | 降血糖的保健食品及其制备方法 | |
CN102526138B (zh) | 鲜马齿苋降血糖有效组分组合物及制备方法 | |
CN102526203B (zh) | 一种具有抗糖尿病肾病作用的香椿子提取物制备方法 | |
CN107041924A (zh) | 一种防治糖尿病肾病的朝药复方提取物及其制备方法 | |
CN106938011A (zh) | 一种具有降血糖作用的中药及制备方法 | |
CN106692742A (zh) | 一种调节血糖的中药复方药物及其制备方法 | |
CN102579530A (zh) | 具有抗糖尿病作用的太白楤木总皂苷的制备方法及药物 | |
CN1931233B (zh) | 一种用于治疗心脑血管疾病的丹参和淫羊藿的药用组合物 | |
CN105250989A (zh) | 一种用于抗疲劳的阿胶小肽组合物 | |
CN105106300A (zh) | 青钱柳提取物在制备防治非酒精性脂肪肝的药物中的应用 | |
IBRAHIM et al. | Glucose and Lipid Lowering Potentials of Heliotropium indicum L. Leaves in Alloxan-Induced Hyperglycaemic Rats | |
CN104116753A (zh) | 桃叶珊瑚苷在制备治疗特发性肺纤维化药物中的应用 | |
CN105535070B (zh) | 治疗糖尿病的药物组合物及其制备方法和应用 | |
CN109985206A (zh) | 用于防治酒精性肝损伤的组合物 | |
CN104352672A (zh) | 一种含龟板的治疗糖尿病的中药组合物 | |
CN109172667A (zh) | 一种瓯柑果实富含多甲氧基黄酮组分提取物的降糖用途 | |
CN106492008B (zh) | 一种用于制备抗糖尿病肾病产品的中药组方及其制备方法和用途 | |
CN102824423A (zh) | 一种含白芍苷和牛蒡苷的药物组合物及应用 | |
CN102652791A (zh) | 一种具有抗肝纤维化作用的药物组合物及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: WEIFANG MEDICAL COLLEGE Free format text: FORMER OWNER: TIAN JINGZHEN Effective date: 20140130 Free format text: FORMER OWNER: LI WANZHONG Effective date: 20140130 |
|
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 250355 JINAN, SHANDONG PROVINCE TO: 261053 WEIFANG, SHANDONG PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20140130 Address after: 261053 Shandong Province, Weifang city Weicheng District Baotong Street No. 7166 scientific research department of Weifang Medical University Applicant after: WEIFANG MEDICAL University Address before: 250355 Changqing University Science Park, Ji'nan, Shandong, Applicant before: Tian Jingzhen Applicant before: Li Wanzhong |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140312 |
|
CF01 | Termination of patent right due to non-payment of annual fee |